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Abstract
Background: Germline mutations in the FLCN gene are responsible for the development of fibrofolliculomas, lung 
cysts and renal neoplasia in Birt-Hogg-Dube' (BHD) syndrome. The encoded protein folliculin (FLCN) is conserved 
across species but contains no classic motifs or domains and its function remains unknown. Somatic mutations or loss 
of heterozygosity in the remaining wild type copy of the FLCN gene have been found in renal tumors from BHD 
patients suggesting that FLCN is a classic tumor suppressor gene.
Results: To examine the tumor suppressor function of FLCN, wild-type or mutant FLCN (H255R) was stably expressed in 
a FLCN-null renal tumor cell line, UOK257, derived from a BHD patient. When these cells were injected into nude mice, 
tumor development was inversely dependent upon the level of wild-type FLCN expression. We identified genes that 
were differentially expressed in the cell lines with or without wild-type FLCN, many of which are involved in TGF-β 
signaling, including TGF-β2 (TGFB2), inhibin β A chain (INHBA), thrombospondin 1 (THBS1), gremlin (GREM1), and SMAD3. In 
support of the in vitro data, TGFB2, INHBA, THBS1 and SMAD3 expression levels were significantly lower in BHD-
associated renal tumors compared with normal kidney tissue. Although receptor mediated SMAD phosphorylation 
was not affected, basal and maximal TGF-β-induced levels of TGFB2, INHBA and SMAD7 were dramatically reduced in 
FLCN-null cells compared with FLCN-restored cells. Secreted TGF-β2 and activin A (homo-dimer of INHBA) protein levels 
were also lower in FLCN-null cells compared with FLCN-restored cells. Consistent with a growth suppressive function, 
activin A (but not TGF-β2) completely suppressed anchorage-independent growth of FLCN-null UOK257 cells.
Conclusions: Our data demonstrate a role for FLCN in the regulation of key molecules in TGF-β signaling and confirm 
deregulation of their expression in BHD-associated renal tumors. Thus, deregulation of genes involved in TGF-β 
signaling by FLCN inactivation is likely to be an important step for tumorigenesis in BHD syndrome.
Background
Birt-Hogg-Dubé (BHD) syndrome is a familial disorder
that predisposes patients to develop hair follicle hamar-
tomas (84-90% penetrance), lung cysts (85% penetrance)
and renal neoplasia (29-34% penetrance) [1-5]. BHD
patients are at risk to develop bilateral, multifocal renal
tumors with a variety of histologies, mainly chromo-
phobe (34%) and oncocytic hybrid (50%) tumors with fea-
tures of both chromophobe renal cell carcinoma (RCC)
and renal oncocytoma. Clear cell and papillary RCC as
well as renal oncocytomas are also found in BHD patients
at a low frequency [6]. The BHD syndrome locus was
mapped to chromosome 17p11.2 by linkage analysis in
BHD families, and germline mutations in a novel gene
FLCN (alias BHD), were identified and characterized [5,7-
11]. Most BHD families carry germline mutations pre-
dicted to truncate the encoded protein, folliculin (FLCN),
including insertion/deletion, nonsense, and splice-site
mutations reported in several large BHD cohorts [4,5,11].
Either somatic "second hit" mutations predicted to trun-
cate the protein or loss of heterozygosity at the BHD syn-
drome locus was identified in 70% of renal tumors from
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BHD patients [12] supporting a tumor suppressor func-
tion for FLCN.
Two naturally-occurring animal models have been
described that show phenotypes similar to BHD patients.
The Nihon rat model develops renal carcinoma with clear
cell histology by 6 months of age and harbors a cytosine
insertion mutation in exon 3 of rat Flcn [13]. A canine
model of BHD, which develops renal cystadenocarci-
noma and nodular dermatofibrosis (RCND), carries a
germline missense mutation (H255R) in canine Flcn [14].
Recently, we and others described a conditional Flcn
knockout mouse model in which Flcn inactivation was
targeted to mouse kidney using the Cre-lox site-specific
recombination system. The affected mice displayed renal
hyperplasia, formation of multiple cysts and renal dys-
function, suggesting important roles for Flcn in regula-
tion of renal cell proliferation [15,16]. No tumors formed
before the animals died at 3 weeks of age due to renal fail-
ure, and therefore the mechanism by which Flcn inactiva-
tion leads to kidney cancer could not be examined in this
in vivo model. However, recently we and others have
reported that mice heterozygous for Flcn develop renal
cysts and tumors as they age beyond a year [17-19], with
d e m o n s t r a t e d  l o s s  o f  t h e  w i l d  t y p e  c o p y  o f  Flcn  (17).
These Flcn +/- mouse models more closely mimic BHD
syndrome in the human, albeit with a long latency.
FLCN encodes a 64 kDa protein with no characteristic
functional domains, which forms a complex with novel
folliculin-interacting proteins 1 and 2 (FNIP1 and
FNIP2), and 5'-AMP-activated protein kinase (AMPK),
an important energy sensor in cells that negatively regu-
lates mammalian target of rapamycin (mTOR) [20,21].
Phosphorylation of FLCN and FNIP1 was regulated by
AMPK and mTOR activities suggesting a functional rela-
tionship with the AMPK-mTOR pathway. Interestingly,
activation of mTOR downstream signaling molecules was
seen in kidney-targeted BHD  conditional knockout
mouse kidneys [15,16]. In addition, the renal tumors from
BHD patients showed increased phosphorylation of
mTOR [15]. In contrast to these results, it was suggested
that yeast homologs of FLCN  and  TSC1/2  may have
opposing roles in amino acid homeostasis [22]. The cysts
and renal tumors derived from the Flcn  heterozygous
mice described by Hartman et al. showed reduced phos-
pho-S6R suggesting diminished mTOR activation [18].
On the other hand Hasumi and coworkers found upregu-
lation of both mTORC1 and mTORC2 pathways in kid-
ney tumors from Flcnd/+ mice [17]. Hudon et al. suggest
that up or down regulation of m TOR by inactivation of
Flcn in a mouse model may be context-dependent [19].
Thus it is possible that mTOR signaling is regulated dif-
ferently by FLCN depending on cell types or experimen-
tal conditions.
A renal cancer cell line (UOK257) established from a
BHD patient was recently developed and characterized
[23]. UOK257 cells harbor a cytosine insertion in a
(poly)C tract, the frequently mutated "hot spot" within
exon 11 of FLCN (c.1285dupC), and have lost the wild-
type copy of FLCN. Cytogenetic analysis revealed that the
cell line was nearly triploid displaying multiple unbal-
anced translocations and deletions of chromosomes. The
MYC copy number was heterogeneous in UOK257 cells
ranging from 3 to 5 copies. These cells formed tumors in
immunodeficient mice (SCID/BEIG) exhibiting predomi-
nantly atypical clear epithelial cell type histology, as well
as a variety of other histologic types including tubular
papillary, and foci reminiscent of chromophobe RCC, all
of which resemble the histologies within the tumor from
which the cell line was derived [23].
In the current study, in order to investigate the tumor
suppressor function of FLCN we have introduced wild-
type  FLCN  into UOK257 cells and compared their
growth  in vitro and  in vivo. We found that wild-type
FLCN suppressed tumor cell growth in vivo, confirming
the tumor suppressor function of FLCN. In addition, we
employed gene expression microarray analysis to identify
novel downstream target genes of FLCN. Among the dif-
ferentially expressed genes, we identified several critical
genes involved in TGF-β signaling including TGFB2,
INHBA, THBS1, GREM1 and SMAD3. Since deregula-
tion of TGF-β signaling is important in tumorigenesis
and tumor progression, we characterized the expression
of these genes in FLCN-null and FLCN-expressing cul-
tured cells as well as in renal tumors surgically removed
from BHD patients. In addition, we examined the growth
suppressive effect of activin A in the FLCN-null cell line
and investigated receptor mediated TGF-β signaling in
FLCN-null and FLCN-restored cell lines.
Results
Wild-type FLCN expression was restored in UOK257 cells by 
lentiviral vectors
To evaluate the tumor suppressor function of FLCN,
wild-type or mutant (H255R) FLCN  cDNA was intro-
duced into the FLCN-null UOK257 cells using lentiviral
vectors. Four clones expressing wild-type FLCN
(UOK257-2, -3, -4, and -6) and one clone expressing
mutant  FLCN-H255R  (UOK257-H255R;  Flcn  missense
mutation responsible for canine RCND) were isolated
and compared to the parental UOK257 cells (UOK257-P).
FLCN protein expression was measured by Western blot
analysis using a mouse monoclonal anti-FLCN antibody.
Relatively high levels of FLCN protein were detected in
the UOK257-2, -4 and -6 cells but very low levels of
FLCN protein were detected in the UOK257-3 and
UOK257-H255R cells (Fig. 1A). FLCN mRNA expressionHong et al. Molecular Cancer 2010, 9:160
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from both the transgene and endogenous FLCN was mea-
sured by quantitative RT-PCR. The total FLCN mRNA
expression was increased by the expression of the wild-
type FLCN or mutant FLCN-H255R transgene to varying
degrees in the cell lines (P = 3 < 4 < H255R <2 <6) (Fig.
1B).
Anchorage independent but not dependent growth of 
UOK257 cells was inversely correlated with wild-type FLCN 
expression
We examined whether introduction of wild-type or
mutant  FLCN  could affect anchorage dependent and
independent growth of UOK257 cells. Anchorage depen-
dent growth of UOK257 cells on culture dishes was not
affected by the expression of wild-type or mutant FLCN
(Fig. 1C). However, anchorage independent growth mea-
sured as colony numbers on soft agar was low in the wild-
type FLCN cell line UOK257-2, which expressed high lev-
els of FLCN, compared to the parental UOK257 cell line
(UOK257-P) (Fig. 1D). One of the characteristics of the
UOK257 cells was a slow growth rate (doubling time,
52+/- 9 hrs) on culture dishes. These cells also grew very
slowly in soft agar taking 3-4 weeks to reach a countable
colony size. By comparison, HT-1080 cells derived from a
fibrosarcoma grew faster in soft agar and often generated
larger colonies (data not shown).
Tumor growth was suppressed by wild-type FLCN but not 
by mutant FLCN-H255R expression
To examine whether the tumorigenic potential of
UOK257 cells was affected by wild-type or mutant FLCN,
mutant  FLCN (UOK257-P and -H255R) and wild-type
FLCN-expressing cells (UOK257-2, -3, -4 and -6) were
injected subcutaneously with matrigel into athymic nude
mice and tumor growth was measured for up to one year.
Most of the mice injected with UOK257-P and UOK257-
H255R cells developed solid tumors, although some ani-
mals only developed flat patches of tumor cells (See addi-
Figure 1 Characterization of the UOK257 cell lines. (A) FLCN protein expression in the UOK257 cell lines restored with wildtype or mutant FLCN. P, 
parental; HR, FLCN (H255R) mutant; 2, 3, 4 and 6, wildtype FLCN. (B) FLCN mRNA level was measured by quantitative RT-PCR. Columns, mean; bars, +SD 
(n = 3). (C) Cell growth of the UOK257 cell lines in vitro. Points, mean (n = 4). (D) Colony formation assay of the UOK257 cell lines and control HT1080 
cell line in soft-agar culture. Columns, mean; bars, +SD (n = 3).Hong et al. Molecular Cancer 2010, 9:160
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tional file 1: Table S1 and Fig. 2A). All of these tumors
were high grade and exhibited clear cell histology (See
additional file 1: Table S1 and Fig. 2B). On the other hand,
the mice injected with UOK257 cells expressing a high
level of FLCN (UOK257-2, -4 and -6) did not develop
t u m o r s  ( S e e  a d d i t i o n a l  f i l e  1 :  T a b l e  S 1  a n d  F i g .  2 A ) .
Instead, flat masses of cells only rarely containing tumor
cells were observed in 6 of 35 (17%) of the animals. The
mice injected with UOK257-3 cells expressing a very low
level of FLCN developed solid tumors with low incidence
(2/10) and smaller size (See additional file 1: Table S1). In
some animals, UOK257-3 cells grew as flat patches (5/10;
Fig. 2A) and exhibited mostly clear cell histology with
varying grades (low to high; Fig. 2B).
We investigated whether wild-type or mutant FLCN
transgenes, or the endogenous mutant FLCN genes were
lost during tumor progression. Genomic DNA was iso-
lated from the tumors or tumor cell patches and PCR was
performed using a primer pair specific to exon 10 and
exon 11 that amplifies 664 bp of the endogenous FLCN
gene or 99 bp of the FLCN transgene. All of the tumors
from the cell lines retained the endogenous mutant FLCN
gene (c.1285dupC) and all of the tumors from UOK257-3
and UOK257-H255R retained their respective transgenes
(See additional file 1: Fig. S1).
Gene expression microarray analysis identified genes 
regulated by FLCN and the pathways in which they interact
To identify the genes regulated by FLCN expression, we
performed gene expression microarray analysis using
RNAs isolated from the UOK257 cell lines expressing
either no, mutant or wild-type FLCN. We identified a
total of 439 genes, which were up or down-regulated
more than 2-fold in the mutant and FLCN-null cell lines
(UOK257-P and UOK257-H255R) compared to the wild-
type FLCN cell lines (UOK257-2, -3, -4 and -6) (See addi-
tional file 2: Table S2). To explore the biological processes
and pathways regulated by FLCN, the genes were subclas-
sified with the help of "Panther Classification System"
http://www.pantherdb.org and three prominent pathways
were identified, namely cadherin signaling, TGF-β signal-
ing, and angiogenesis (Fig. 3A). Although all three of
these pathways are important in tumorigenesis, we
focused on the genes involved in TGF-β signaling (See
a d d i t i o n a l  f i l e  1 :  F i g .  S 2 ) .  W e  f o u n d  t h a t  TGF-β2
(TGFB2), Inhibin β A (INHBA, a subunit of activin A),
SMAD3 (SMAD3) and thrombospondin-1 (THBS1) were
down-regulated, and Gremlin (GREM1) was upregulated
in  FLCN-null  and mutant FLCN-H255R  UOK257 cells
compared with FLCN-restored UOK257 cells. We con-
firmed the GREM1, TGFB2, INHBA, SMAD3 and THBS1
Figure 2 Suppression of tumorigenesis by re-introduction of wild-type FLCN not mutant FLCN in the FLCN-null cell line, UOK257. (A) Tum-
origenesis of UOK257 cells in nude mice was suppressed by wild-type FLCN. Arrow indicates a tumor from UOK257-P cells. Arrowhead indicates a flat 
patch of tumor cells from UOK257-3 cells. (B) Histologies of the tumors from different clones of UOK257 cells. (a) high, (b) medium, and (c) low grade 
clear cell histologies; (d) papillary RCC.Hong et al. Molecular Cancer 2010, 9:160
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microarray results by quantitative RT-PCR (See addi-
tional file 1: Fig. S3).
Knockdown of FLCN deregulates TGFB2, INHBA, GREM1, 
THBS1 and SMAD3 expression in FLCN-restored UOK257 
cells
We next examined whether the expression levels of
TGFB2, INHBA, THBS1, GREM1 and SMAD3 could be
deregulated by knockdown of FLCN in  FLCN-restored
UOK257 cells. A FLCN-knockdown cell line was gener-
ated by introducing a retrovirus that expressed shRNA
against  FLCN  in  FLCN-restored cells (UOK257-2). In
addition to reduced expression of FLCN, the expression
of TGFB2, INHBA, THBS1 and SMAD3 was decreased
and the expression of GREM1  was increased in the
FLCN-knockdown cell line (Fig. 3B).
GREM1, TGFB2, INHBA, THBS1 and SMAD3 expression levels 
were down-regulated in BHD-associated renal tumors
In order to determine whether the genes that were regu-
lated by FLCN in in vitro cell culture were differentially
expressed in renal tumors from BHD patients compared
to normal kidney parenchyma, we performed quantita-
tive RT-PCR using RNA isolated from these tissues.
GREM1, TGFB2,  INHBA,  THBS1  and  SMAD3  RNA
expression levels were significantly lower in the BHD
renal tumors compared to normal kidney tissue (Fig. 4A).
However, FLCN RNA levels were not statistically differ-
ent (P = 0.316). In support of the RT-PCR data, immuno-
histochemical staining of TGF-β2 showed strong TGF-β2
expression in the normal renal tubules but reduced
expression in the tumors from BHD patients (Fig. 4B, left
panel). In addition, the UOK257 xenograft tumors
expressed lower levels of TGFB2 compared to normal
mouse kidney (Fig. 4B, right panel).
We measured protein expression of SMAD2, SMAD3,
phospho-SMAD3 (pSMAD3) and FLCN in renal tumors
from BHD patients (n = 11) and normal human kidney
tissue (n = 5). pSMAD3 levels were high in 3 out of 5 nor-
mal kidneys but only 1 (T11) of 11 tumors (Fig. 4C). In
addition, SMAD3 levels and SMAD3/SMAD2 ratios were
higher in normal kidneys compared to the tumors. On
the other hand FLCN protein levels were lower or unde-
tectable in all tumors except T11, in which a moderate
level of FLCN expression was detected along with high
levels of pSMAD3 and SMAD3 (Fig. 4C). Therefore it is
likely that the T11 tumor was contaminated with normal
kidney tissue.
In order to investigate whether receptor mediated
TGF-β signaling was disrupted by the loss of FLCN
expression, TGF-β induced SMAD3 phosphorylation was
Figure 3 Genes differentially expressed in mutant and wild-type FLCN cell lines. (A) Heat-map representation of the genes differentially ex-
pressed in mutant and wild-type FLCN cell lines, and hierarchical clustering of the cell lines. Gene symbols are listed on the left side of each row. Three 
prominent groups of genes involved in signaling pathways were indicated on the left side of the gene symbols. (B) Deregulation of the key molecules 
in TGF-β signaling by FLCN knockdown in the UOK257-2 cells expressing wildtype FLCN. C, control cell line infected with empty retrovirus; KD, FLCN-
knockdown cell line infected with a retrovirus expressing short hairpin RNA targeting FLCN.Hong et al. Molecular Cancer 2010, 9:160
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Figure 4 Genes involved in TGF-β signaling and the encoded proteins dysregulated in renal tumors from BHD patients. (A) Quantitative RT-
PCR of TGFB2, INHBA, SMAD3, THBS1, GREM1 and FLCN expression levels in human BHD tumors (T, n = 12) and normal kidneys (N, n = 8). Gene expres-
sions were normalized against cyclophilin gene expression and relative expressions were calculated against gene expression in UOK257 cells. Median 
values of expression levels were indicated with short lines. Points, mean expression of each sample. P value, Mann-Whittney U-test. (B) Reduced ex-
pression of TGF-β2 in the BHD tumors (left panel) and the UOK257 xenograft tumors (right panel) compared to normal renal tubules as shown by 
immunohistochemical staining. Five BHD tumors were examined and a representative immunostained image is shown. (C) Positive correlation of 
pSMAD3 and SMAD3 with FLCN expression in human BHD kidney tumors and normal kidney tissue. pSMAD3, SMAD2, SMAD3 and FLCN protein levels 
were measured by western blot analysis in normal kidney tissue (n = 5) and BHD tumors (n = 11).Hong et al. Molecular Cancer 2010, 9:160
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examined in UOK257 cells and compared to UOK257-2
cells. TGF-β induced SMAD3 phosphorylation was not
a f f e c t e d  b y  F L C N  i n a c t i v a t i o n  ( F i g .  5 A ) .  I n  a d d i t i o n ,
BMP4 induced SMAD1/5/8 phosphorylation was not dis-
rupted by loss of FLCN expression (data not shown). We
then examined whether TGF-β induced gene expression
was dysregulated in FLCN-null UOK257 cells. SMAD7,
an inhibitory SMAD, is known to be induced by TGF-β.
SMAD7  expression was induced in both UOK257 and
UOK257-2 cell lines (Fig. 5B). However the basal and the
maximal induced levels of SMAD7 were two fold greater
in UOK257-2 cells than in UOK257 cells. Similar to
SMAD7, TGFB2 and INHBA expressions were induced
by TGF-β in both cell lines but their basal and maximal
levels of expression were substantially higher (5.8- to 23-
fold) in FLCN-restored UOK257-2 cells compared with
FLCN-null UOK257 cells (Fig. 5B).
Since FLCN and FNIP1/2 can complex with AMPK,
and phosphorylation of these proteins is affected by
AMPK and mTOR signaling, we wanted to know whether
AMPK and mTOR signaling affected the expression of
TGFB2 and INHBA in a FLCN -dependent manner. Inter-
estingly, both TGFB2 and INHBA were induced by the
AMPK activator AICAR but reduced by the AMPK
inhibitor Compound C in UOK257-2 cells expressing
FLCN as well as in cells in which FLCN expression was
knocked down by a retrovirus expressing FLCN shRNA
[UOK257-2/FLCN-KD; Fig. 5C(a) and Fig. 5C(b)].
Rapamycin, an inhibitor of mTOR signaling, also induced
TGFB2 and INHBA expression in both FLCN-expressing
UOK257-2 and UOK257-2/FLCN-KD cells [Fig. 5C(a)
and Fig. 5C(b)]. However, the basal and maximal levels of
induction of TGFB2 and INHBA by AICAR and rapamy-
cin were higher in FLCN-expressing UOK257-2 cells
compared to UOK257-2/FLCN-KD cells [Fig. 5C(a) and
Fig. 5C(b)]. Similar results were obtained from an experi-
ment using UOK257 FLCN-null and UOK257-2 FLCN-
expressing cell lines. Interestingly, AICAR induced
TGFB2 and INHBA expression in UOK257-2 cells but not
in UOK257 cells [Fig. 5C(c) and Fig. 5C(d)].
Activin A but not TGF-β2 suppressed anchorage-
independent growth of UOK257 cells
Initially, in order to confirm that protein expression levels
were consistent with the mRNA expression levels, we
measur ed secr eted T GF-β2 and activin A leve ls in the
media of UOK257 and UOK257-2 cells by ELISA. In
accordance with their mRNA expression, TGF-β2 and
activin A protein expression levels were lower in UOK257
cells compared to UOK257-2 cells (Fig. 6A and 6B). Since
both TGF-β2 and activin A have been reported to sup-
press cell growth, we examined their effect on growth of
UOK257 cells. To evaluate the growth suppressive effects
of TGF-β2 and activin A, UOK257 cells were treated with
TGF-β2 or activin A and cultured for 4 weeks in soft-agar.
Unexpectedly, TGF-β2 appeared to increase colony for-
mation of UOK257 cells at both 1 ng/ml and 5 ng/ml (Fig.
6C). However, activin A reduced colony formation at 1
ng/ml and completely suppressed colony formation at 5
ng/ml (Fig. 6D).
Discussion
UOK257 is the only renal cancer cell line available to date
that has been established from a BHD patient's tumor tis-
sue. This cell line is particularly valuable for study of the
biological role of FLCN  inactivation in tumorigenesis
because it harbors a FLCN mutation predicted to produce
only truncated mutant protein and induces the growth of
tumors in vivo with histology resembling the BHD-asso-
ciated renal tumor from which it was derived [23]. In this
study, we have established and characterized UOK257
cell lines in which wild-type or mutant FLCN was stably
expressed. Although anchorage dependent cell growth in
vitro was not affected by wild-type FLCN expression, cell
growth in vivo and anchorage-independent growth in soft
agar were severely diminished by the expression of wild-
type  FLCN. We have searched for downstream target
genes regulated by FLCN  through gene expression
microarray analysis and identified a number of genes that
were differentially expressed in wild-type FLCN
(UOK257-2, -4, and -6) compared with mutant FLCN and
FLCN-null (UOK257-H255R and -P) cells. We found
three prominent groups of genes involved in cadherin
signaling, TGF-β signaling, and angiogenesis. Notably,
several key genes involved in TGF-β signaling, such as
TGFB2, INHBA, THBS1 and SMAD3, were down-regu-
lated in FLCN-null and mutant FLCN cells as well as in
the BHD-associated renal tumors. Consistently, GREM1,
the antagonist of BMP that signals through SMADs was
highly up-regulated in mutant FLCN  and  FLCN-null
UOK257 cells although its expression was low in BHD-
associated renal tumors.
We observed that the expression level of FLCN is
important for tumor suppression, since the UOK257 cell
lines (UOK257-4, -2 and -6) expressing high levels of
FLCN did not develop tumors whereas the UOK257-3
cell line expressing a very low level of FLCN, did develop
tumors with a low incidence (2 out of 10). It is likely that
the FLCN expression level in UOK257-3 cells is marginal
for tumor suppression, allowing tumor growth in some
animals but suppressing tumor growth in others. In sup-
port of this idea, the expression levels of the downstream
target genes in UOK257-3 cells were either similar to
FLCN-null  and  FLCN  mutant cells (UOK257-P and
UOK257-H255R), or midway between the FLCN-null-
FLCN  mutant group and the FLCN-restored group,
which expressed high levels of FLCN (UOK257-2 and
UOK257-6) (See additional file 1: Fig. S3).Hong et al. Molecular Cancer 2010, 9:160
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Figure 5 TGF-β1 induced SMAD3 phosphorylation and effects of AICAR, Compound C and rapamycin on TGF- β1 induction of TGFB2 and 
INHBA in FLCN-null and FLCN-expressing cells. (A) TGF-β1 induced SMAD3 phosphorylation in UOK257 and UOK257-2 cells. Cells were treated with 
0, 0.1 and 1 ng/ml of TGF-β1 for 1 hr. (B) TGF-β1 induced TGFB2, INHBA and SMAD7 mRNA expression in UOK257 and UOK257-2 cells. Cell were treated 
with 1 ng/ml of TGF-β1 for 0, 6, 12 and 24 hr after serum starvation for 12 hr. (C) (a and b) Cells were serum-starved for 24 hr and treated with 0.5 mM 
AICAR (AI), 20 μM Compound C (CC) or 1 nM rapamycin (Rapa) for 12 hr. UOK257-2/vector, UOK257-2 cells infected with empty retrovirus; UOK257-2/
FLCN-KD, UOK257-2 cells infected with retrovirus expressing shRNA targeting FLCN. (c and d) Cells were serum-starved for 15 hr and treated with 0.5 
mM AICAR or 20 μM Compound C (CC) for 6 hr.Hong et al. Molecular Cancer 2010, 9:160
http://www.molecular-cancer.com/content/9/1/160
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Figure 6 Higher levels of secreted TGF-β2 and activin A proteins were detected in FLCN-restored UOK257-2 cells compared to the parental 
UOK257 cell line. (A) TGF-β2 and (B) activin A levels in cultured media were measured by ELISA (R&D systems). (C) TGF-β2 induced anchorage inde-
pendent growth of UOK257 cells. However, (D) activin A suppressed anchorage independent growth of UOK257 cells. UOK257 cells (2,500 cells) were 
plated in soft-agar and cultured for 4 weeks in the presence of TGF-β2 or Activin A and stained with crystal violet. N = 4 for each treatment.Hong et al. Molecular Cancer 2010, 9:160
http://www.molecular-cancer.com/content/9/1/160
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UOK257-H255R cells expressed a low level of FLCN
protein resulting in loss of tumor suppressor function
and deregulation of TGF-β signaling, even though they
expressed slightly more FLCN mRNA than UOK257-4
cells (Fig.1A and 1B). These data suggest that FLCN-
H255R missense mutant protein found in the canine
model of BHD syndrome is less stable than wild-type
FLCN. Thus decreased stability of mutant FLCN is likely
to contribute to the loss of FLCN tumor suppressor func-
tion.
It has been suggested that Drosophila BHD (dBHD)
regulates germline stem cell (GSC) maintenance down-
stream or in parallel with Jak/Stat and dpp (BMP ortholog
in  Drosophila) signaling [24]. dBHD  knockdown by
siRNA suppressed overproliferation of GSC induced by
hyperactivation of Jak/Stat or dpp signaling. Interestingly,
Jak1, encoding a kinase that transmits signals by phos-
phorylating Stats in cells, was identified by microarray
analysis as a downregulated gene in the mutant FLCN
and FLCN-null cells (Fig. 3A). We also identified several
key genes in TGF-β/BMP signaling such as TGFB2,
INHBA, THBS1 and SMAD3 (a regulatory SMAD) that
were down-regulated in the mutant FLCN and FLCN-null
cells. On the other hand, GREM1, which encodes a pro-
tein that binds and inactivates BMP activity, was upregu-
lated in the mutant and FLCN-null cells. Thus the genetic
interactions between dBHD, and Jak/Stat and dpp (BMP)
signaling may be partially explained by FLCN deregula-
tion of genes involved in these pathways.
The human TGF-β superfamily consists of 42 members
including TGF-βs, activins, bone morphogenic proteins
(BMPs), and growth and differentiating factors (GDFs)
[25,26]. TGF-βs are multi-functional cytokines that mod-
ulate cell proliferation, apoptosis, differentiation, adhe-
sion and migration. TGF-β shows a biphasic effect on
tumor cell growth [27]. It inhibits tumor cell growth in
the early phase of tumorigenesis but promotes cell
growth when cells escape the anti-proliferative effect of
TGF-β in the late phase of tumorigenesis. Interestingly,
TGF-β2 induced anchorage independent growth of
UOK257 cells (Fig. 6C), suggesting that UOK257 cells are
refractory to the growth suppressive effect of TGF-β. The
possibility exists that reduced expression of TGF-β2 in
FLCN-null cells contributed to cell growth in the early
phase of tumorigenesis.
Disruption of TGF-β signaling has been reported in
many cancers. TGF-β type II receptor is often mutated in
gastro-intestinal cancers [28-30]. Mutations in SMAD2
or SMAD4 occur frequently in pancreatic and colorectal
carcinomas [31-33]. Although mutations in SMAD3 have
not been reported, 3 out of 8 (37.5%) gastric tumors in
one report showed low to undetectable levels of SMAD3
expression and restoration of SMAD3 suppressed tum-
origenicity of gastric cancer cells [34]. Low levels of
SMAD3 expression in the BHD tumors may contribute to
the ability of these renal tumor cells to escape the growth
suppressive effect of TGF-β.
Activins are homo- or heterodimeric proteins consist-
ing of two β subunits (βA and βB), while inhibins are het-
erodimers of α and β subunits (inhibin-A [αβA] and
inhibin-B [αβB]) [35]. INHBA is one of the β subunits
(βA) that comprise activin A (βAβA), activin AB (βAβB)
and inhibin A (αβA). Activin A regulates kidney organo-
genesis, tubular regeneration and renal fibrosis [reviewed
in [36]]. Activins also induce apoptosis, and inhibit cell
proliferation and tumor growth in numerous types of
cells. In contrast to TGF-β2, activin A inhibited growth of
UOK257 cells in soft-agar (Fig. 6D), suggesting that
activin signaling is intact in UOK257 cells. Thus reduced
expression of INHBA, β subunit of activin A, in UOK257
cells and BHD tumors, may be permissive for tumor cell
growth. It would be interesting to examine whether
activin A treatment can suppress BHD tumor growth in
vivo.
Thrombospondin-1 (THBS1) is one of the five mem-
bers of a family of thrombospondins that mediate the
interaction of normal and cancer cells with the extracellu-
lar matrix and surrounding tissue. THBS1 suppresses
tumor growth by activating TGF-β and by inhibiting
angiogenesis. THBS1 exerts direct effects on endothelial
cell migration and survival through interaction with
CD36. It also reduces availability of VEGF by inhibiting
MMP9, therefore releasing VEGF from the extracellular
matrix. There are several reports suggesting that reduced
expression of THBS1 or hypermethylation of THBS1 is
associated with poor prognosis of cancer patients and
higher tumor grade [37-40]. Accordingly THBS1 regula-
tion may be an important part of the tumor suppressor
function of FLCN.
We examined whether TGF-β signaling is dysregulated
by the inactivation of the FLCN gene. TGF-β or BMP4
induced SMAD3 or SMAD1/5/8 phosphorylation was
not affected by FLCN inactivation suggesting receptor
mediated SMAD phosphorylation is not altered by
FLCN. However, several genes whose expressions are reg-
ulated by TGF-β were dysregulated by the inactivation of
FLCN. The basal and maximal induced levels of the
downstream target genes (TGFB2, INHBA and SMAD7)
regulated by TGF-β were reduced in cells with FLCN
inactivation. These data suggest that FLCN may regulate
TGF-β signaling through a non-SMAD mediated mecha-
nism. As a result of such regulation, the level of TGF-β
ligands, such as TGF-β2 and activin A, could be highly
induced in cells expressing FLCN by a positive feedback
control.
A  p o s s i b l e  f u n c t i o n  o f  F L C N  i n  e n e r g y  s e n s i n g  a n d
metabolism has been suggested by its interaction with
AMPK through FNIP1/2 and by the observation thatHong et al. Molecular Cancer 2010, 9:160
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FLCN phosphorylation is affected by mTOR signaling
(20-21). Here we demonstrated that an AMPK activator,
AICAR, and an AMPK inhibitor, Compound C, as well as
an mTOR inhibitor, rapamycin, affected the expression of
the same key molecules involved in TGF-β signaling,
which appear to be regulated by FLCN. Thus FLCN could
be a key molecule connecting energy-sensing signals to
growth suppressive TGF-β signaling.
Conclusions
Here for the first time we have confirmed the tumor sup-
pressor function of FLCN in vivo and identified new
potential FLCN downstream targets in the TGF-β signal-
ing pathway. This study will provide a foundation for
understanding the pathogenesis of BHD syndrome at the
molecular level and be useful for finding therapeutic tar-
g e t s  f o r  t r e a t i n g  B H D - a s s o c i a t e d  k i d n e y  c a n c e r  a n d
potentially, sporadic chromophobe RCC. We are cur-
rently analyzing the mechanism by which FLCN regulates
these target genes and the functional importance of
deregulation of these FLCN target genes in tumorigene-
sis.
Methods
Establishment of cell lines, cell culture, and cell growth
Wild-type or mutant (H255R) FLCN cDNA was trans-
duced into UOK257 cells using the ViraPower Lentiviral
expression system (Invitrogen) following the manufac-
turer's protocols. Stable clones were selected using Blasti-
cidin S (1.5 μg/ml). Cells were maintained in DMEM
medium supplemented with 10% fetal bovine serum
(FBS) and penicillin/streptomycin. To evaluate growth
rate in culture, cells (2 × 103) were plated in each well of
five 96 well plates, cultured, and cell numbers were mea-
sured at day 1, 2, 3, 5 and 7 using the CyQuant Cell Prolif-
eration Assay Kit (Molecular Probes). Adenoviral vectors
(pAd/CMV/V5-DEST) expressing wild-type and mutant
(c.1285dupC) FLCN were generated using the ViraPower
Adenoviral Gateway system (Invitrogen) following the
manufacturer's protocol. A retroviral shRNA vector tar-
geting FLCN was generated by inserting double stranded
oligonucleotides (forward sequence, 5'-GATCCCC GGT-
GTTTGAGGCAGAGCAGTTCAAGAGACTGCTCTG
CCTCAAACACCTTTTTA-3' and reverse sequence, 5'-
GCTTAAAAAGGTGTTTGAGGCAGAGCAGTCTCT-
TGAACTGCTCTGCCTCAAACACCGGG-3') into Hin-
dIII and BglII sites of pSuper-Retro vector (Oligoengine)
following the manufacturer's instruction. UOK257-2 cells
were infected with the FLCN shRNA vectors and selected
against puromycin (7.5 ug/ml).
Colony formation assay
UOK257 cells (5 × 103) were suspended in 1.5 ml of 0.3%
agar in DMEM containing 10% FBS and were overlayed
on 1.5 ml of pre-solidified 0.5% agar in the same medium.
C e l l s  w e r e  cu l t u r ed  i n  a  C O 2 incubator for 3-4 weeks.
Colonies were stained for 1 hour with 0.02% crystal violet
solution dissolved in 10% neutral formalin. Colony num-
ber was counted under a dissection microscope after
washing with PBS three times.
Tumor growth in nude mice
Cells (1 × 106) suspended with basement membrane
matrix (BD Biosciences) were injected subcutaneously
into the flanks of athymic nude mice. Tumor growth was
measured once a week and mouse health was monitored
daily. Mice bearing tumors larger than 2 cm, or showing
severe health problems, were sacrificed and examined.
Otherwise tumor growth was monitored for up to one
year after injection. Tumors were fixed in 10% buffered
formalin solution for histological examination and flash
frozen in liquid nitrogen for protein and RNA extraction.
Animal care procedures followed NCI-Frederick Animal
Care and Use Committee guidelines.
Immunoblotting
Cells were harvested and lysed in RIPA buffer (50 mM
Tris-Cl, pH 8.0 with 150 mM NaCl, 1.0% NP-40 and 0.5%
sodium deoxycholate) or 1× SDS sample buffer (Biorad).
Cell lysates were resolved by 4-20% SDS PAGE and blot-
ted onto PVDF membrane. The following antibodies
were used in this study: anti-FLCN mouse monoclonal
[20], anti-β-actin (Sigma), anti-SMAD2/3 (Santa Cruz,
sc-6032), and anti-pSMAD2/3 (Santa Cruz, sc-11769)
antibodies. Immunoblots were processed by the ECL
Detection System (Pierce) according to the manufac-
turer's protocols.
Immunohistochemistry
Paraffin tissue sections were deparaffinized, rehydrated
in graded alcohol and boiled in Tris-EDTA buffer pH 8.0
for 20 min at 90°C for antigen retrieval. After blocking,
sections were probed with primary antibodies overnight
and then incubated with HRP-polymer conjugated sec-
ondary antibodies. Diaminobenzidine hydrochloride
(DAB) was used as a substrate for peroxidase. Sections
were then briefly counterstained with hematoxylin and
permanently mounted for observation.
ELISA
Cells (2 × 105) were cultured on 6 well plates for 3 days
and culture media was collected for assay. TGF-β2, and
activin A levels in the media were quantified by Human
TGF-β2 DuoSet (R&D systems) and activin A DuoSet
(R&D systems), respectively, following the manufac-
turer's instruction.
RNA isolation, microarray analysis and pathway analysis
Total RNAs were isolated from the UOK257 cell lines
using Trizol reagent (Invitrogen) and further purified
using RNeasy mini kit (QIAGEN) according to the manu-Hong et al. Molecular Cancer 2010, 9:160
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facturer's protocols. Probes, which were generated using
these RNAs, were hybridized to the Human Genome
U133 Plus 2.0 arrays (Affymetrix) and processed accord-
ing to recommended protocols. The CEL files were pro-
cessed using the Partek Genomic Suite 6.2 (Partek Inc.).
Data were transformed using a log normalization process
and the differentially expressed genes were identified by
Student's t-test and Mann-Whitney U-test. The genes
that were differentially expressed in mutant FLCN cell
lines (UOK257-P and -H255R) and wild-type FLCN cell
lines (UOK257-2, -4 and -6) were used for further analy-
sis.
Quantitative real-time reverse transcription-PCR (RT-PCR)
To confirm the microarray results, quantitative real-time
reverse transcription PCR (RT-PCR) was performed.
RNAs were digested with DNase I for 30 min at 37°C fol-
lowed by heat denaturation at 70°C for 20 min to remove
genomic DNA contamination. Total RNAs (2.5 μg) were
primed with 100 ng random primers and reverse-tran-
scribed by Superscript II reverse transcriptase (Invitro-
gen) at 42°C for 1 hr. The identical reactions were
performed without reverse transcriptase to generate neg-
ative controls. PCR primers were generated using Primer
3 software [41] or Primer Express 3.0 (Applied Biosys-
tems). Quantitative RT-PCR was performed with Power
SYBR-Green or Taqman Gene Expression Master Mix
(Applied Biosystems) using a 7300 Real-Time PCR system
(Applied Biosystems) following the manufacturer's proto-
cols. All reactions were run in triplicate using β-actin,
GAPDH or cyclophilin A genes as internal controls. The
relative level of a particular gene expression was evalu-
ated according to the function of 2-ddCt, where ddCt is
dCt(treatment) - dCt(control), dCt is Ct(target gene) - Ct(GAPDH or
actin) and Ct is the cycle at which the threshold is crossed.
The gene-specific primer pairs for the PCR reactions are
as follows: FLCN  forward 5'-TTCACGCCATTCCTA-
CACCAGA-3' and reverse 5'-GCCCACAGGTTGTCAT-
CACTTG-3',  GREM1  forward 5'-GCAAAACCCAGC
CGCTTAA-3' and reverse 5'-TGATGGTGCGACTGTT-
GCA-3', TGFB2 forward 5'-CGAGAGGAGCGACGAA-
GAGT-3' and reverse 5'-AGGGCGGCATGTCTA
TTTTG-3',  THBS1  forward 5'-CCAGATCAGGCAGA-
CACAGA-3' and reverse 5'-AGTTGTCCCGTTCATT-
GAGG-3',  INHBA  forward 5'-TGGAGTGTGATG
GCAAGGTCA-3' and reverse 5'-GCATGATAGCCA-
GAGGGAGCA-3', SMAD3 forward 5'-GACGAGGTCT-
GCGTGAATCC-3' and reverse 5'-GTGGCGTGGCACC
AACA-3', and GAPDH  forward 5'-TTCCACCCATG-
GCAAATTCC-3' and reverse 5'-CGCCCCACTT-
GATTTTGGAG-3'.  SMAD7  forward 5'-CCAACTGC
AGACTGTCCAGA-3' and reverse 5'-CAGGCTCCA-
GAAGAAGTTGG-3'. PCR product quality was moni-
tored using post-PCR dissociation curve analysis.
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